Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 14/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451188 | 0.84 | RAB9A (0.61) | RAB9AMAPTNPSR1EPHX1NPC1 | |
| SCHEMBL590532 | 0.83 | EPHX1 (0.59) | RAB9AMAPTNPSR1EPHX1ACHE | |
| SCHEMBL4430601 | 0.82 | EPHX1 (0.50) | RAB9AMAPTNPSR1EPHX1ACHE | |
| SCHEMBL17443826 | 0.82 | EPHX1 (0.50) | RAB9AMAPTNPSR1EPHX1ACHE | |
| SCHEMBL1126445 | 0.81 | ACHE (0.52) | RAB9AMAPTNPSR1EPHX1NPC1 | |
| SCHEMBL5160852 | 0.81 | EPHX1 (0.48) | RAB9AEPHX1NPC1SMN1; SMN2ACHE | |
| SCHEMBL1233113 | 0.79 | — | — | |
| SCHEMBL9197261 | 0.79 | EPHX1 (0.55) | RAB9AMAPTNPSR1EPHX1ACHE | |
| SCHEMBL5163094 | 0.79 | EPHX1 (0.47) | RAB9AEPHX1NPC1SMN1; SMN2ACHE | |
| SCHEMBL8532896 | 0.79 | EPHX1 (0.56) | RAB9AMAPTEPHX1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3990455-A1 | PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264081-A1 | PROCESSES FOR PREPARING TOLL-LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2015130445-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130444-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | WO | disclosed |
| EP-2785715-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013080222-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2013-06-06 | — | — | WO | disclosed |
| EP-2238134-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| WO-2010025448-A2 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009080705-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-1989203-A2 | ALPHA CARBOLINES AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1430074-A1 | AMINOGLYCOSIDE LIPID DERIVATIVES FOR TRANSFECTION | Aventis Pharma S.A. (FR) | 2004-06-23 | — | — | EP | disclosed |
| EP-1385822-A1 | AMINOPYRROLIDINE SULFONAMIDES AS SERINE PROTEASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003018603-A1 | AMINOGLYCOSIDE LIPID DERIVATIVES FOR TRANSFECTION | AVENTIS PHARMA S.A. (FR) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002076945-A1 | AMINOPYRROLIDINE SULFONAMIDES AS SERINE PROTEASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-0889877-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0876365-A1 | SUBSTITUTED QUINOLYLMETHYLEN-OXINDOLE ANALOGUES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997046551-A1 | SUBSTITUTED QUINOLYLMETHYLEN-OXINDOLE ANALOGUES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997036862-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | RAB9A 2127/4885MAPT 3484/4885NPSR1 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.